<DOC>
	<DOCNO>NCT00098579</DOCNO>
	<brief_summary>This phase I trial study side effect best dose alvocidib give doxorubicin hydrochloride treat patient metastatic recurrent sarcoma remove surgery . Drugs use chemotherapy , doxorubicin hydrochloride alvocidib , work different way stop growth tumor cell , either kill cell stop dividing . Alvocidib may also help doxorubicin hydrochloride work well make tumor cell sensitive drug . Giving one drug may kill tumor cell</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Alvocidib Treating Patients With Metastatic Recurrent Sarcoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine maximum tolerate dose flavopiridol ( alvocidib ) administer fix dose doxorubicin ( doxorubicin hydrochloride ) patient unresectable metastatic locally recurrent sarcoma . SECONDARY OBJECTIVES : I . Determine clinical pharmacokinetics regimen patient . II . Determine , preliminarily , therapeutic activity regimen patient . III . Correlate pRb , p53 , p21 protein level treatment response apoptosis patient treat regimen . IV . Correlate NMR biochemical pattern response patient treat regimen . OUTLINE : This open-label , dose-escalation study alvocidib . Patients receive doxorubicin hydrochloride intravenously ( IV ) 5-10 minute alvocidib IV 1 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients reach cumulative doxorubicin dose 600 mg/m^2 experience cardiotoxicity may receive alvocidib alone discretion investigator . Cohorts 3-6 patient receive escalate dos alvocidib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Ten additional patient receive treatment MTD . Patients follow every 3 month 1 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Histologically cytologically confirm softtissue sarcoma* Unresectable disease Locally recurrent metastatic disease Disease amenable biopsy ( patient treat maximum tolerated dose ) No know prior concurrent brain metastasis Performance status Karnofsky 60100 % Performance status ECOG 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal Creatinine ≤ 1.5 mg/dL Creatinine clearance ≥ 60 mL/min Ejection fraction ≥ 50 % MUGA echocardiogram No uncontrolled hypertension No myocardial infarction No New York Heart Association class IIIV congestive heart failure No unstable angina No serious cardiac arrhythmia require medication No peripheral vascular disease ≥ grade 2 within past year No clinically significant cardiac disease No prior deep vein thrombosis No prior vascular thrombus No prior pulmonary embolism Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No symptomatic peripheral neuropathy ≥ grade 2 No malignancy within past 5 year except adequately treat basal cell skin cancer carcinoma situ cervix Carcinoma situ consider second malignancy No history allergic reaction attribute compound similar chemical biologic composition study drug No psychiatric illness social situation would preclude study compliance No ongoing active infection No uncontrolled illness See Chemotherapy At least 3 week since prior immunotherapy recover At least 3 week since prior chemotherapy ( 6 week carmustine mitomycin ) recover No 2 prior cytotoxic chemotherapy regimens Peroxisome proliferatoractivated receptor ( PPAR ) gamma agonist , thalidomide , target therapy ( i.e. , tyrosine kinase inhibitor include imatinib mesylate , sorafenib , sunitinib malate ) count prior chemotherapy regimen No prior anthracyclines At least 3 week since prior radiotherapy recover No prior extensive radiotherapy bone marrowproducing site ( e.g. , radiotherapy pelvis spine ) At least 1 week washout period since prior tyrosine kinase inhibitor target therapy Concurrent lowdose warfarin ( 1 mg per day ) prevent thrombus central line allow No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>